Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 Apr 17, 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study” Abstract Number: 02980 Poster Number: PO423 Day: April 27, 2024 Time: 12:00 p.m. CEST / 6:00 a.m. ET Session Location: Poster Area Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact) Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.